Interactive Features

Quiz

Front-Line Treatment Options for Ovarian Cancer

12/20/2023

Oncology

Quiz

New and Emerging Targeted Therapies for Relapsing Ovarian Cancer

11/29/2023

Oncology

Quiz

Maintenance Olaparib Rechallenge for Ovarian Cancer

10/31/2023

Oncology

Quiz

Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer

05/16/2023

How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?

How is Sleeping Beauty...

05/16/2023

Oncology

Quiz

Quiz: FDA Approves Mirvetuximab Soravtansine

12/15/2022

What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?

What treatment must patients...

12/15/2022

Oncology

Quiz

Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice

12/02/2022

What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?

What is the most prevalent...

12/02/2022

Oncology

Quiz

Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer

11/03/2022

A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?

A phase 3 open-label study found...

11/03/2022

Oncology

Quiz

Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer

03/27/2022

True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.

True or false: Researchers at...

03/27/2022

Oncology

Test Your Knowledge

Quiz: A Common Thread in Rising Endometrial Cases in US Women

05/29/2021

Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?

Quiz: Among young adult women in...

05/29/2021

Oncology

Test Your Knowledge

Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?

05/28/2021

True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.

True or False: Study findings...

05/28/2021

Oncology

Recent News

FDA Approval

FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot

09/23/2026

Stephanie Holland

The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...

The FDA approved Amneal’s...

09/23/2026

Oncology

News

NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening

09/23/2026

Stephanie Holland

Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...

Results from the randomized...

09/23/2026

Oncology

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology